Sept. 22, 2023
by Andrii Buvailo
Interview
In the dynamic field of life sciences, both biological research and AI are coming together to alter our perspective on …
Sept. 13, 2023
by Andrii Buvailo
Interview
Biotechnology is more than just an emerging scientific frontier, it also impacts global economy, competition, and societal transformation. To learn …
Sept. 3, 2023
by Andrii Buvailo
Interview
In August, AbbVie has secured European Commission (EC) approval for AQUIPTA® (atogepant) as a preventive treatment for adults experiencing four …
July 10, 2023
by Andrii Buvailo
Interview
Navigating the dynamic intersection of biology and data science, Eduardo Abeliuk, the CEO of TeselaGen Biotechnology, invites us on a …
June 15, 2023
by Andrii Buvailo
Interview
We're fortunate to speak with Dr. James Field, founder and CEO of LabGenius, a leading machine learning (ML)-driven protein engineering …
April 18, 2023
by Andrii Buvailo
Interview
With BioNTech’s recent $200 million merger with OncoC4’s cancer drug, the demand for personalised medicines to treat diseases such as cancer …
March 14, 2023
by Andrii Buvailo
Interview
In this interview, we speak with Mark Andrews, Investment Director, Life Sciences, Funds at British Patient Capital, the largest domestic …
March 1, 2023
by Andrii Buvailo
Interview
Recently, David Dowling, a senior lawyer at Ropes & Gray, has outlined his predictions for M&A in the European biotech …
Jan. 17, 2023
by Sabina Lee
Interview
Sponsored by Syntekabio
Before the age of modern drug discovery, the pharmaceutical industry had been plagued with uncertainty and processing challenges, including the …
Dec. 28, 2022
by Andrii Buvailo
Interview
The aging research industry has exploded in recent years. Once a fringe area of science, aging research has now gained …
Dec. 22, 2022
by Andrii Buvailo
Interview
The medical device industry is driven by constant innovation, and the annual Medica conference offers the chance to discover the …
Nov. 6, 2022
by Andrii Buvailo
Interview
While the pharmaceutical world is investigating biologics or mRNA-based therapies, Yochi Slonim, Israeli technology and biotech entrepreneur and public speaker …